1. Transparency in economic evaluations

   • Suzanne Hill

   Editorial 17 September 2012 Pages: 967 - 969

2. Measuring health-related quality of life in older patient populations

   • Anne Hickey
   • Maja Barker
   • Ciaran O’Boyle

   Review Article 17 September 2012 Pages: 971 - 993

   

3. Pharmacological management of overactive bladder

   • Denis Getsios
   • Wissam El-Hadi
   • J. Jaime Caro

   Review Article 17 September 2012 Pages: 995 - 1006

   

4. The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden

   • Peter Hertzman

   Original Research Article 17 September 2012 Pages: 1007 - 1020

   

5. Using policy simulation to predict drug plan expenditure when planning reimbursement changes

   • Colin R. Dormuth
   • Sean Burnett
   • Sebastian Schneeweiss

   Original Research Article 17 September 2012 Pages: 1021 - 1030

   

6. Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease

   • Dyfrig A. Hughes
   • Keith Bodger
   • Dominique Dubois

   Original Research Article 17 September 2012 Pages: 1031 - 1041

   

7. Financial impact of two different ways of evaluating early virological response to peginterferon-α-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1

   • Maria Buti
   • Miguel A. Casado
   • Rafael Esteban

   Original Research Article 17 September 2012 Pages: 1043 - 1055

   

8. Eplerenone

   • Katherine F. Croom
   • Greg L. Plosker

   Adis Pharmacoeconomic Drug Evaluation 17 September 2012 Pages: 1057 - 1072